BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 288 filers reported holding BIO-TECHNE CORP in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $9,478,739 | +532.8% | 24,818 | +214.2% | 0.08% | +388.2% |
| Q1 2020 | $1,498,000 | +156.5% | 7,900 | +196.9% | 0.02% | +240.0% |
| Q4 2019 | $584,000 | -67.3% | 2,661 | -68.9% | 0.01% | -61.5% |
| Q2 2019 | $1,786,000 | +98.2% | 8,565 | +88.8% | 0.01% | +85.7% |
| Q1 2019 | $901,000 | -1.5% | 4,537 | +1.2% | 0.01% | +16.7% |
| Q3 2018 | $915,000 | +58.6% | 4,483 | +14.9% | 0.01% | +100.0% |
| Q2 2018 | $577,000 | +52.2% | 3,901 | +55.5% | 0.00% | +50.0% |
| Q1 2018 | $379,000 | -22.0% | 2,509 | -37.6% | 0.00% | -33.3% |
| Q3 2017 | $486,000 | +90.6% | 4,019 | +85.2% | 0.00% | +50.0% |
| Q2 2017 | $255,000 | -72.6% | 2,170 | -76.3% | 0.00% | -71.4% |
| Q1 2017 | $929,000 | +116.0% | 9,144 | +118.4% | 0.01% | +250.0% |
| Q4 2016 | $430,000 | -15.4% | 4,186 | -7.2% | 0.00% | 0.0% |
| Q2 2016 | $508,000 | -70.7% | 4,509 | -75.4% | 0.00% | -80.0% |
| Q1 2016 | $1,736,000 | +27.2% | 18,363 | +24.4% | 0.01% | +25.0% |
| Q3 2015 | $1,365,000 | +288.9% | 14,765 | +314.3% | 0.01% | +300.0% |
| Q2 2015 | $351,000 | -64.5% | 3,564 | -63.9% | 0.00% | -66.7% |
| Q1 2015 | $989,000 | +375.5% | 9,865 | +337.9% | 0.01% | +500.0% |
| Q4 2014 | $208,000 | – | 2,253 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |